​Haleon plc:
Director/PDMR Shareholding
​
1 November 2024: Haleon plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today
announces notification and public disclosure in accordance with the
requirements of The UK Market Abuse Regulation of Transactions by a
Person Discharging Managerial Responsibilities ("PDMR").
This notification sets out the
details of the grants of Haleon share awards over ordinary shares
(grant date - 31 October 2024) made to Dawn Allen as CFO
(incoming), under the Haleon Performance Share Plan 2023 and Share
Value Plan 2023.
Further to the announcement on 24
April 2024, relating to Dawn's appointment as CFO with effect from
1 November 2024, Dawn has received awards to compensate the loss of
incentive payments from her previous employment. These awards will
vest subject to continued employment and performance conditions
where appropriate, and will mirror as closely as possible the
value, terms and release timeline of the forfeited
awards.
In addition, a Performance Share
Plan (Interim) award has been granted on a pro-rated basis to
reflect Dawn's start date of 28 October 2024. This award is subject to continued employment and
performance conditions over the performance period ending 31
December 2026 (vesting in March 2027). Performance targets were
disclosed in the 2023 Annual Report and Form 20-F.
All awards are subject to malus and
clawback provisions.
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Dawn Allen
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Financial Officer
(incoming)
|
|
b)
|
Initial notification
/Amendment
|
Initial
Notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction
monitor
|
|
a)
|
Name
|
Haleon plc
|
|
b)
|
LEI
|
549300PSB3WWEODCUP19
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Ordinary Shares of £0.01
each
|
|
|
|
|
Identification
code
|
GB00BMX86B70
|
|
|
|
|
b)
|
Nature of the
transaction
|
(i)
Grant of a conditional award under the Haleon plc
Performance Share Plan (Buyout) subject to
performance conditions over a performance period ending 31 March
2025 (vesting in June 2025, with an
additional post vest 2 year holding period).
(ii)
Grant of a conditional award under the Haleon plc
Performance Share Plan (Buyout) subject to
performance conditions over the performance period ending on 31
December 2025 (vesting in June 2026 with an
additional post vest 2 year holding period).
(iii)
Grant of a conditional award under the Haleon plc
Performance Share Plan (Buyout) subject to
performance conditions over the performance period ending on 31
December 2026 (vesting in June 2027 with an
additional post vest 2 year holding period).
(iv)
Grant of a conditional award under the Haleon plc
Share Value Plan (Buyout) vesting in November 2024
(with an additional post vest 2 year holding
period).
(v)
Grant of a conditional award under the Haleon plc
Share Value Plan (Buyout) vesting in June
2025.
(vi)
Grant of a conditional award under the Haleon plc
Performance Share Plan (Interim) subject to
performance conditions over the performance period ending on 31
December 2026 (vesting in March 2027 with an additional post vest 2
year holding period).
|
|
c)
|
Price(s) and
volume(s)
|
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
(i)
|
Nil
|
355,191
|
|
|
|
|
(ii)
|
Nil
|
334,272
|
|
|
|
|
(iii)
|
Nil
|
190,369
|
|
|
|
|
(iv)
|
Nil
|
158,653
|
|
|
|
|
(v)
|
Nil
|
41,484
|
|
|
|
|
(vi)
|
Nil
|
170,334
|
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
|
|
|
- Aggregated volume
|
1,250,303
|
|
|
|
|
- Price
|
Nil
|
|
|
|
|
e)
|
Date of the
transaction
|
31 October 2024
|
|
f)
|
Place of the
transaction
|
Outside a trading venue
|
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a global
leader in consumer health, with a purpose to deliver better
everyday health with humanity. Haleon's product portfolio spans
five major categories - Oral Health, Pain Relief, Respiratory
Health, Digestive Health and Other, and Vitamins, Minerals and
Supplements (VMS). Its long-standing brands - such as Advil,
Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident,
parodontax and Centrum - are built on trusted science, innovation
and deep human understanding.
For more information, please
visit www.haleon.com.
